Psyence Biomedical Reschedules Shareholder Meeting After Quorum Shortfall
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Psyence Biomedical ( (PBM) ) just unveiled an update.
On January 22, 2026, Psyence Biomedical Ltd. announced that it had adjourned its annual and special meeting of shareholders, originally scheduled for that day, because it failed to achieve the requisite quorum. The company has rescheduled the meeting for February 12, 2026, to be held in Cape Town, South Africa, and confirmed that the record date for voting entitlement remains December 23, 2025, as it works with proxy agents to secure sufficient shareholder participation for the reconvened meeting.
More about Psyence Biomedical
Psyence Biomedical Ltd. is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. Listed on Nasdaq, it focuses on developing nature-derived (non-synthetic) psilocybin- and ibogaine-based psychedelic medicines aimed at addressing unmet mental health needs through an evidence-based approach and the development of safe, effective, regulator-approved treatments for a broad range of mental health disorders.
Average Trading Volume: 1,535,171
Technical Sentiment Signal: Sell
Current Market Cap: $677.5K
For detailed information about PBM stock, go to TipRanks’ Stock Analysis page.
